Mapi-Pharma (MAPI)

Developing extended-release formulations of existing drugs and generics.

Health Care -

IPO Performance
Latest Trade ()
First Day Return
Return from IPO
 
Mapi-Pharma IPO News more
  • .
IPO Data
IPO File Date 03/26/2014
Offer Price
Price Range $15.00 - $17.00
Offer Shares (mm) 3.1
Deal Size ($mm) $50
 
IPO Data
IPO Date
Offer Price
Price Range $15.00 - $17.00
Offer Shares (mm) 3.1
Deal Size ($mm) $$50
 
Underwriters
more
Business Overview
We are a clinical stage pharmaceutical company, engaged in the development of improved extended-release versions of existing commercially successful products, which we refer to as life cycle management, or LCM products, that target large markets, as well as high-barrier to entry and high-added value generic drugs.
We are a clinical stage pharmaceutical company, engaged in the development of improved extended-release versions of existing commercially successful products, which we refer to as life cycle management, or LCM products, that target large markets, as well as high-barrier to entry and high-added value generic drugs.
more
Company Data
Headquarters Ness Ziona, , Israel
Founded 2008
Employees 23
Website www.mapi-pharma.com
 

Performance vs. IPO Index (IPOUSA)